JPS649938A - Oral ingestive composition - Google Patents

Oral ingestive composition

Info

Publication number
JPS649938A
JPS649938A JP62163510A JP16351087A JPS649938A JP S649938 A JPS649938 A JP S649938A JP 62163510 A JP62163510 A JP 62163510A JP 16351087 A JP16351087 A JP 16351087A JP S649938 A JPS649938 A JP S649938A
Authority
JP
Japan
Prior art keywords
oral
ingestive
oral administration
peptide
mentioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62163510A
Other languages
Japanese (ja)
Inventor
Susumu Maruyama
Noboru Tomizuka
Hideo Suzuki
Ryuji Sugai
Umeji Murakami
Taira Takemoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology, Kanebo Ltd filed Critical Agency of Industrial Science and Technology
Priority to JP62163510A priority Critical patent/JPS649938A/en
Publication of JPS649938A publication Critical patent/JPS649938A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE:To obtain an oral ingestive composition containing a compound peptide or acid addition salt thereof as an active ingredient, having high safety and effective in oral administration. CONSTITUTION:An oral ingestive composition containing a peptide expressed by the formula or acid addition salt thereof as an active ingredient. The above- mentioned peptide is a partial structural substance of bovine casein and obtained by hydrolyzing the above-mentioned protein with trypsin. An organic chemical synthetic technique can be more advantageously used. Although physiologically active peptides are difficult to exhibit effective physiological activity by oral administration because of hydrolysis and inactivation by digestive tract juice or malabsorption from digestive tracts, etc., the afore-mentioned peptides exhibit powerful hypotensive action by oral administration.
JP62163510A 1987-06-30 1987-06-30 Oral ingestive composition Pending JPS649938A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62163510A JPS649938A (en) 1987-06-30 1987-06-30 Oral ingestive composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62163510A JPS649938A (en) 1987-06-30 1987-06-30 Oral ingestive composition

Publications (1)

Publication Number Publication Date
JPS649938A true JPS649938A (en) 1989-01-13

Family

ID=15775236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62163510A Pending JPS649938A (en) 1987-06-30 1987-06-30 Oral ingestive composition

Country Status (1)

Country Link
JP (1) JPS649938A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039730A1 (en) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Oral preparations containing peptides promoting the secretion of growth hormone
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8802628B2 (en) 2008-08-15 2014-08-12 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US10675325B2 (en) 2010-08-11 2020-06-09 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039730A1 (en) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Oral preparations containing peptides promoting the secretion of growth hormone
US8802628B2 (en) 2008-08-15 2014-08-12 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US10675325B2 (en) 2010-08-11 2020-06-09 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US10702576B2 (en) 2010-08-11 2020-07-07 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide

Similar Documents

Publication Publication Date Title
Du Vigneaud et al. The synthesis of oxytocin1
NO922232L (en) PHYSIOLOGICALLY ACTIVE, POLYPEPTIDE-CONTAINING, PHARMACEUTICAL PREPARATIONS
BR9507811B1 (en) polypeptides and pharmaceutical composition.
ATE124997T1 (en) ENZYMATIC REMOVAL OF AN AMINOTERMINAL PROTEIN SEQUENCE.
SE9301172D0 (en) PROCEDURES FOR PREPARING A PEPTIDAL ALCOHOL
NO882732L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
MY132924A (en) Hematopoietic stimulation
TR200101049T2 (en) Cyclic tetrapeptide compound and its use
EP0130779A3 (en) Pharmaceutical composition suitable for intestinal administration
DK193887D0 (en) PHYSIOLOGICALLY ACTIVE PEPTID
NO871295D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
NO870049D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
DE69123278D1 (en) Use of short chain fatty acids containing lipids to maintain the integrity and function of the gastrointestinal tract
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
JPS649938A (en) Oral ingestive composition
GR3002835T3 (en) Pharmaceutical compositions containing pentamidine
FI93843C (en) Process for producing an angiogenic factor
ATE72120T1 (en) USE OF PETASITES EXTRACTS IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES.
Gladner et al. The biological properties of peptides derived from fibrinogen
EP0383481A3 (en) Anesthetic oral compositions
Abel et al. Some hitherto undescribed properties of the constituents of Witte's peptone
EP0261088A3 (en) Process for the production of heparanlysopeptide sulphate, the product thus obtained and its therapeutic use
RU94037232A (en) Peptides showing organ-protective activity, method of their synthesis and their use
JPS6423899A (en) Novel physiologically active polypeptide